Depsipeptide (FK228), a new histone deacetylase inhibitor, has been recently introduced into clinical trials. This agent shows interesting metabolic properties, novel mechanism of action, and is undergoing phase I-II clinical studies in hematopoietic malignancies and solid tumors. Mechanism of action, pharmacokinetics and anticancer activity of depsipeptide is the subject of this review.
Keywords: Epigenetic therapy, histone deacetylase inhibitors, depsipeptide (FK228), cutaneous T-cell lymphoma, solid tumors
Rights & PermissionsPrintExport